{"id":"W3204548506","doi":"10.1016/j.annonc.2021.08.2089","title":"LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pembrolizumab; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Taxane; Clinical trial; Cancer; Cisplatin; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00239446,0.001836859,0.003314147,0.0004965282,0.0005743891,0.001242212,0.001370728,0.00197642,0.01036231],"category_scores_gemma":[0.001697536,0.0008308158,0.002444269,0.0003989645,0.001197694,0.001160056,0.0004245891,0.004107559,0.001771699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008967099,"about_ca_system_score_gemma":0.001663653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001459635,"about_ca_topic_score_gemma":0.003313643,"domain_scores_codex":[0.9993947,0.0002914936,0.00004188333,0.0001137762,0.00004700105,0.0001111249],"domain_scores_gemma":[0.9991448,0.0002328786,0.0001653213,0.00007409789,0.00005881414,0.0003240147],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9646935,0.007676682,0.0002388026,0.000825349,0.001147742,0.00002146933,0.00004342039,0.0003534509,0.00517001,0.0001251404,0.001303358,0.01840112],"study_design_scores_gemma":[0.9420298,0.05512688,0.0009603595,0.00003755643,0.0004921443,0.00001697873,0.00001417099,0.0002162169,0.0004384717,0.0001007921,0.00055098,0.00001568161],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9690728,0.01050573,0.001994431,0.001262416,0.00136137,0.007164408,0.003772686,0.0005287736,0.004337384],"genre_scores_gemma":[0.9711929,0.00549076,0.003825771,0.002233993,0.0006440629,0.005974304,0.003324913,0.0001093134,0.007203862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01036231,"threshold_uncertainty_score":0.03466535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1454233936655726,"score_gpt":0.4294092977272955,"score_spread":0.2839859040617229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}